UBS Group Cuts Davita (NYSE:DVA) Price Target to $60.00

Davita (NYSE:DVA) had its price objective decreased by analysts at UBS Group from $61.00 to $60.00 in a report released on Thursday, BenzingaRatingsTable reports. The firm currently has a “neutral” rating on the stock. UBS Group’s target price points to a potential upside of 6.14% from the stock’s current price.

Other analysts also recently issued reports about the company. Robert W. Baird downgraded Davita from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $70.00 to $65.00 in a report on Friday, July 26th. Deutsche Bank cut their target price on Davita from $68.00 to $66.00 and set a “buy” rating on the stock in a research note on Thursday, May 9th. TheStreet upgraded Davita from a “c+” rating to a “b-” rating in a research note on Wednesday, July 24th. William Blair reiterated a “buy” rating on shares of Davita in a research note on Thursday, June 20th. Finally, ValuEngine lowered Davita from a “hold” rating to a “sell” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company. Davita has a consensus rating of “Hold” and a consensus target price of $67.21.

Shares of DVA stock traded down $0.05 on Thursday, hitting $56.53. The stock had a trading volume of 23,457 shares, compared to its average volume of 4,366,191. The company has a quick ratio of 1.10, a current ratio of 1.12 and a debt-to-equity ratio of 1.90. The business has a 50 day moving average price of $58.12 and a 200 day moving average price of $54.42. The company has a market cap of $9.13 billion, a PE ratio of 15.83, a P/E/G ratio of 0.55 and a beta of 1.59. Davita has a one year low of $43.40 and a one year high of $79.11.

Davita (NYSE:DVA) last released its quarterly earnings data on Thursday, August 1st. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.12. The firm had revenue of $2.84 billion during the quarter, compared to the consensus estimate of $2.86 billion. Davita had a return on equity of 14.67% and a net margin of 1.21%. The firm’s quarterly revenue was down 1.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.05 earnings per share. Equities research analysts expect that Davita will post 4.74 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of DVA. Pendal Group Ltd purchased a new position in Davita in the first quarter valued at about $1,585,000. Invesco Ltd. grew its stake in shares of Davita by 56.2% during the second quarter. Invesco Ltd. now owns 3,662,685 shares of the company’s stock worth $206,063,000 after acquiring an additional 1,317,725 shares during the last quarter. Par Capital Management Inc. grew its stake in shares of Davita by 40.6% during the second quarter. Par Capital Management Inc. now owns 4,159,000 shares of the company’s stock worth $233,985,000 after acquiring an additional 1,201,300 shares during the last quarter. Pictet Asset Management Ltd. grew its stake in shares of Davita by 3,290.3% during the second quarter. Pictet Asset Management Ltd. now owns 1,132,521 shares of the company’s stock worth $63,716,000 after acquiring an additional 1,168,020 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale grew its stake in shares of Davita by 1,512.8% during the second quarter. DekaBank Deutsche Girozentrale now owns 724,095 shares of the company’s stock worth $40,159,000 after acquiring an additional 679,199 shares during the last quarter. Institutional investors own 88.90% of the company’s stock.

About Davita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Featured Story: Different Options Trading Strategies

Analyst Recommendations for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.